A Peer-reviewed, open access journal sponsored by TMR publishing group
Editor-in-Chief: Dan Chen, PhD. Prof.
ISSN 2624-3075
7Drug Combination Therapy is an international peer-reviewed, open access journal sponsored by TMR publishing group. DCT aims to publish unbiased original articles, reviews, letters, news and comment in all areas of drug combination therapy. DCT is dedicated to report the latest advancements and the research done in drug combination along with all the relevant fields, including but not limited to prescription compatibility studies, disassembled formulae studies, drug compatibility synergetic/antergic mechanisms, drug incompatibility/adverse reactions, combination therapy for specific populations, integrated pharmacology studies, system/network pharmacology, big data analysis, systematic evaluation/meta-analysis, omics research, natural products chemistry, pharmaceutical analysis, etc. In order to focus on breakthrough research in a field, DCT insist on publishing special issues around a topic related to drug combination therapy. DCT has been included in EuroPub, Google Scholar, CNKI Scholar, VIP Data, Superstar Journals Database and Traditional Medicine Research Data Expanded. ... More

Topics More

Call for PaperMore

Current Issue     09 November 2019, Volume 1 Issue 4 Previous Issue   
For Selected: View Abstracts Toggle Thumbnails

Orginal Article
Systematic pharmacology analysis of Sodium 8-(((carboxymethyl)amino)methyl)-4’,7-bishydroxy-isoflavone-3’-sulfonate
Ze-Ping Luo, Li-Wei Pan, Hai-Lin Chen, Jun-Yu Lu
7Drug Combination Therapy. 2019, 1 (4): 186-198.   https://doi.org/10.12032/DCT201904005
Abstract ( 49 )     PDF (1125KB) ( 6 )  
The purpose of this study is to use the newly synthesized molecule Sodium 8-(((carboxymethyl)amino)methyl)-4’,7-bishydroxy-isoflavone-3’-sulfonate (M) as a research object, the pharmacological mechanism of the molecule was analyzed by using a series of Systematic pharmacology methods. The results show that the M molecule has a higher drug-like DL value of 0.59 and better molecular property parameters, namely Hdon=4, Hacc=10 and AlogP=0.94; A total of 11 M molecules related targets, namely F2, ESR1, AR, F10, CA2, DPP4, CCNA2, PRSS1, CDK2, GSK3B and PTPN1; A total of 140 diseases are associated with M molecule targets, and these diseases are mainly related to cancer and cardiovascular diseases; A total of 52 pathways involve the pharmacological mechanisms of M molecules, which are mainly related to cancer and other related diseases; GO-enriched analysis showed that these targets are closely related to the regulation of peptidase activity and biological processes such as blood coagulation and hemostasis. This article clearly demonstrated the pharmacological mechanism of M molecule, which provides references for exploring the pharmacological mechanism of new compounds.
Data Mining
Analysis of prescription rules in the treatment of diabetic heart disease based on traditional Chinese medicine inheritance support system
Jing-Na Zhou, Xiao-Ting Ma, Guo-Wei Zhang
7Drug Combination Therapy. 2019, 1 (4): 199-209.   https://doi.org/10.12032/DCT201904003
Abstract ( 44 )     PDF (372KB) ( 7 )  
Diabetes is a common clinical disease and has many complications, among which diabetic heart disease is the leading cause of death in diabetic patients. This article collected the prescriptions for the treatment of diabetic heart disease, and used the traditional Chinese medicine inheritance support system to explore the prescription formulation rules. Finally, we included 43 prescriptions for analysis. We found that the rules of formulas for treating diabetic heart disease are complex, but Chinese medicines in these formulas are mainly with the effects of nourishing Qi, nourishing Yin and activating blood circulation. At the same time, we obtained 3 new prescriptions and discussed the clinical rationality of the new prescriptions. The purpose of this article is to provide reference for clinical prescription in the treatment of diabetic heart disease and the development of related new drugs.
A Meta-analysis of the efficacy and safety of Kanglaite injection combined with chemotherapy in the treatment of pancreatic cancer
Lu Zhang, Jia-Jian Lv, Zhe Yang, Shu-Zhen Wu, Jun-Chen Feng, Xin-Juan Wang, Ya-Nan Liu, Xiao-Chun Han
7Drug Combination Therapy. 2019, 1 (4): 210-223.   https://doi.org/10.12032/DCT201903005
Abstract ( 73 )     PDF (761KB) ( 6 )  

Objective: To investigate the efficacy and safety of Kanglaite injection (KLT) combined with chemotherapy in the treatment of pancreatic cancer. Methods: PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Data, and  Chinese Biomedical Database (CBM) were searched to get the studies about KLT plus chemotherapy for pancreatic cancer  (from established to May 2019). Data extraction and bias risk assessment were carried out by two authors independently according to the retrieval method. RevMan (version 5.3) were employed for data analysis. Results: A total of 151 literatures were retrieved and 11 literatures were finally included. A total of 614 patients were included, including 308 in the treatment group and 306 in the control group. The results of meta-analysis showed that compared with chemotherapy alone, KLT combined with chemotherapy could improve the effective rate [PORR = 0.0009, OR=1.96, 95% CI (1.32, 2.92)] and disease control rate [PDCR <0.00001, OR=2.53, 95% CI (1.76, 3.62)], improve KPS score [P<0.00001, OR=3.59, 95% CI (2.00, 6.44)] and body mass indexes [P=0.0003, OR=3.45, 95% CI (1.78, 6.69)], prolong progression free survival (PFS) and overall survival (OS), reduce the rate of myelosuppression [P=0.03, OR=0.54, 95% CI (0.30, 0.95)], but could not reduce the occurrence of neurotoxicity [P=0.49, OR=0.80, 95% CI (0.42, 1.51)] and digestive tract reaction [P=0.51, OR=0.83, 95% CI (0.48, 1.44)]. Conclusion: KLT combined with chemotherapy can improve the curative effect of pancreatic cancer, improve the quality of life of patients, prolong the survival of patients, and reduce the incidence of bone marrow suppression. However, due to the limitation of the quality and quantity of included literatures, this conclusion needs to be verified by high-quality study.

Systematic evaluation and meta-anlysis of the efficacy of Xiaochaihu Decoction in the treatment of chronic superficial gastritis
Shi-Jun Li, Teng Huang, Xiao-Li Ma
7Drug Combination Therapy. 2019, 1 (4): 224-236.   https://doi.org/10.12032/DCT201905001
Abstract ( 35 )     PDF (613KB) ( 4 )  

Objective: To compare the effectiveness of Xiaochaihu Decoction (XCHD) or the modified XCHD combined with western medicine in the treatment of superficial gastritis. Methods: We collected the studies about XCHD or the modified XCHD combined with western medicine for superficial gastritis in China Biology Medicine (CBM) Database (2010-2018), China National Knowledge Infrastructure (CNKI) Database (2010-2018), VIP Database (2010-2018), Wanfang Database (2010-2018) and the Back Issues Database of Hebei University. The randomized controlled trials (RCTs) were included in this study. The literatures were independently extracted by two researchers and the Cochrane Review Handbook (version 5.1.0) was applied to assess the quality of included trials. Statistical analysis was performed with RevMan (version 5.3). Results: A total of 8 RCTs, including 732 cases, were included finally. Meta-analysis results showed that compared with the western medicine treatment group, XCHD or the modified XCHD combined with western medicine could improve the total effective rate [OR=4.67, 95%CI (2.90,7.55), P<0.00001], physiological function [MD=10, 95%CI (8.78,11.23), P<0.00001], role physical [MD=13.85, 95%CI (11.19,16.51), P<0.00001], physical pain [MD=11.64, 95%CI (9.05,14.23), P<0.00001], general health [MD=11.20, 95%CI (9.52,12.88), P<0.00001], vitality [MD=13.46, 95%CI (12.30,14.62), P<0.00001], social function [MD=19.20, 95%CI (17.32,21.09), P<0.00001], affection  function [MD=30.3, 95%CI (28.99,31.62), P<0.00001], mental health [MD=9.80, 95%CI (8.44,11.16), P<0.00001]. Conclusion: XCHD or the modified XCHD combined with western medicine in the treatment of superficial gastritis has good performance in clinical efficacy and the improvement of quality of life. However, with several methodology problems existing in the included RCTs, the effectiveness of XCHD or the modified XCHD is still need more high-quality randomized, double-blind, placebo-controlled trials to further confirmed.

Research progress of Yinchenhao Decoction in the treatment of non-alcoholic fatty liver disease
Xiao-Ting Ma, Jing-Na Zhou, Shou-Jing Sheng, Shao-Qin Ge
7Drug Combination Therapy. 2019, 1 (4): 237-244.   https://doi.org/10.12032/DCT201904004
Abstract ( 55 )     PDF (302KB) ( 3 )  
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Non-alcoholic steatohepatitis (NASH) is the most serious type and a turning point in the progression of NAFLD. If not treated actively, NASH will progress to irreversible liver damage such as cirrhosis and hepatocellular carcinoma. At present, there are no specific therapeutic drugs in western medicine. The treatment methods are mainly to improve lifestyle and exercise therapy, to alleviate the symptoms of discomfort, delay the progress of the disease, and improve the quality of life. However, the effect is often not ideal, prone to recurrence, and compliance is relatively poor. Dramatically, traditional Chinese medicine has certain advantages in the treatment of NAFLD. Modern research has confirmed that Yinchenhao Decoction has a good effect on liver-protective and choleretic action and improving liver function. It has significant curative effect on various liver and gallbladder diseases such as acute liver injury and alcoholic liver disease. This article summarized the clinical and basic research of Yinchenhao Decoction in the treatment of NAFLD. We found that Yinchenhao Decoction can enhance the efficiency of NAFLD and improve symptoms such as dizziness, liver pain, hepatosplenomegaly and indigestion. The mechanisms may be related to that Yinchenhao decoction improves the disorder of glucose and lipid metabolism, inflammatory state and liver function.

TMR Data ExpandedMore



Online FirstMore
    Please wait a minute...